Patent ID: 11896575
Assignee: DELIVRA INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 14:
15. The transdermal formulation of claim 1, wherein:
the hydrophobic active agent is nabilone present in an amount of about 0.05 wt % to about 0.5 wt %, or about 0.05 wt %;
the hydrophobic active agent is buprenorphine present in an amount of about 0.01 wt % to about 0.05 wt %, or about 0.02 wt %;
the hydrophobic active agent is bupivacaine present as hydrochloride in an amount of about 1.0 w t% to about 3.0 wt %, or about 2.0 wt %;
the hydrophobic active agent is lidocaine present in an amount of about 2.0 wt % to about 8.0 wt %, or about 5.0 wt %;
a combination of bupivacaine, lidocaine and epinephrine, wherein the bupivacaine is present as hydrochloride in an amount of about 1.0 wt % to about 3.0 wt %, or about 2.0 wt %, the lidocaine is present in an amount of a about 2.0 wt % to about 8.0 wt %, or about 5.0 wt %, and the epinephrine is present in an amount of about 0.01 wt % to about 0.05 wt %, or about 0.05 wt %; or
the hydrophobic active agent is the synthetic cannabinoid present in an amount of about 1.0 wt % to about 3.0 wt %, or about 1.5 wt %.